Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma Clinical research trials and Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma. Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma clinical trial. Participants frequently get the best healthcare available for their Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "C" Clinical Trials Conditions > Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma



Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

For Condition: Leukemia,adult solid tumor,Lymphoma
Status: Recruiting
Sponsor(s): University of Chicago Cancer Research Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have solid tumors or lymphoma.
Details: OBJECTIVES: Primary - Determine the dose-limiting toxicity, maximum feasible dose, and recommended phase II dose of cilengitide (EMD 121974) in patients with advanced solid tumors or lymphoma. - Determine the safety and tolerability of this drug in these patients. Secondary - Determine the pharmacokinetics of this drug in these patients. - Determine the antineoplastic activity of this drug in these patients. OUTLINE: This is a dose-escalation study. Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A total of 16-26 patients will be accrued for this study within 5.3-13 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor or lymphoma - Refractory to standard therapy or no standard therapy exists - Measurable or evaluable disease - No active brain metastases - Previously treated brain metastases allowed provided the patient is not currently receiving corticosteroids - Primary brain neoplasms allowed, regardless of corticosteroid use PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - WBC 3,000/mm^3 - Absolute neutrophil count 1,500/mm^3 - Platelet count 100,000/mm^3 - No life-threatening bleeding diathesis within the past 6 months Hepatic - Bilirubin normal (unless due to Gilbert's syndrome) Renal - Not specified Cardiovascular - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Gastrointestinal - No prior proven gastric or duodenal ulcer - No clinically significant gastrointestinal blood loss within the past 6 weeks Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No prior CNS hemorrhage - No psychiatric illness or social situation that would preclude study compliance - No other concurrent uncontrolled illness - No ongoing or active infection PRIOR CONCURRENT THERAPY: Biologic therapy - No prior cilengitide (EMD 121974) - No other concurrent biologic therapy Chemotherapy - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - No concurrent chemotherapy Endocrine therapy - See Disease Characteristics Radiotherapy - More than 4 weeks since prior radiotherapy and recovered - No concurrent palliative radiotherapy Surgery - Not specified Other - No other concurrent anticancer agents or therapies intended to treat the malignancy - No other concurrent investigational agents - No concurrent anticoagulation therapy that increases INR or aPTT above the normal range - Line prophylaxis allowed
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
WalterStadler,  Study Chair,  University of Chicago Cancer Research Center

University of Chicago Cancer Research Center *Recruiting*
Chicago,  Illinois,  60637-1470
United States
Recruiting Walter  Stadler 773-702-4400


Additional Information:
Study ID Numbers:  CDR0000349535;  UCCRC-12774A,NCI-6362
Study Start Date: 
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00077155

Other Adult Solid Tumor Studies:
1. Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

2. Phase II Liposomal Vincristine for Pediatric and Adolescent Patients with Relapsed Malignancies

3. Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

4. Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

5. Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Related Studies:

Other adult solid tumor Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Modify your Search

  Other adult solid tumor Clinical Trials
  Other Illinois Clinical Trials
  Other Chicago Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103